Completion of the Ilmenite plant in Q2-23? From what we were told by Management in the May-11 Q1-23 Earnings CC about the Ilmenite plant, a delay in delivery would be difficult to comprehend.
Heiko Ihle: ... Earlier on this earnings call, you brought up the ilmenite concentration plant. I mean, obviously, it should be done quite soon, will be halfway through Q2 on this coming Monday. On a cash basis, how much cash flow do you think you still need to spend from today through the conclusion of ramp up and commissioning for this asset?
Daniel Tellechea: Let me take that as well. I think that the final capital expenditure that we project for the ilmenite plant is done. It might be additional -- additional expenditures in order to close some of the contracts, but really it will be I think a minimum size, the final CapEx is done in the ilmenite plant.
Paul Vollant: Daniel, let me jump in here on this one real quickly. If you are looking at a capitalized perspective, there is not much left, but if you look at the impact on cash, there's probably another 10 million to go on that ilmenite plant. So you will see the impact of that cash over the next sort of four, five months spread out.
Michael Heim: …. Let me ask one about the ilmenite, you've talked about commissioning and ramp up and I think you might have heard some comments that ramp I might go to 2025. Can you just repeat those comments or maybe give answer the question as to how long it will take to actually get to sales? Ernest Cleave: Yes, sure. At this stage, we are anticipating making some of our trial shipments in Q4. So, there would be some revenue is what our anticipation is during Q4. It's not going to be at significant size, but in and around that kind of timing is what we expect right now.